159 related articles for article (PubMed ID: 38048851)
41. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.
Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S
Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583
[TBL] [Abstract][Full Text] [Related]
42. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
43. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
[TBL] [Abstract][Full Text] [Related]
44. Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog.
Mattiuz EL; Ponsler GD; Barbuch RJ; Wood PG; Mullen JH; Shugert RL; Li Q; Wheeler WJ; Kuo F; Conrad PC; Sauer JM
Drug Metab Dispos; 2003 Jan; 31(1):88-97. PubMed ID: 12485957
[TBL] [Abstract][Full Text] [Related]
45. Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.
Giuliano C; Fiore F; Di Marco A; Padron Velazquez J; Bishop A; Bonelli F; Gonzalez-Paz O; Marcucci I; Harper S; Narjes F; Pacini B; Monteagudo E; Migliaccio G; Rowley M; Laufer R
Xenobiotica; 2005; 35(10-11):1035-54. PubMed ID: 16393860
[TBL] [Abstract][Full Text] [Related]
46. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
Mosure KW; Knipe JO; Browning M; Arora V; Shu YZ; Phillip T; Mcphee F; Scola P; Balakrishnan A; Soars MG; Santone K; Sinz M
J Pharm Sci; 2015 Sep; 104(9):2813-23. PubMed ID: 25631585
[TBL] [Abstract][Full Text] [Related]
47. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
[TBL] [Abstract][Full Text] [Related]
48. Metabolism and Disposition of [
Bolleddula J; Chen H; Cohen L; Zhou X; Pusalkar S; Berger A; Sedarati F; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2022 Jul; 50(7):989-997. PubMed ID: 35504658
[TBL] [Abstract][Full Text] [Related]
49. [Pharmacokinetics and disposition of silodosin (KMD-3213)].
Matsubara Y; Kanazawa T; Kojima Y; Abe Y; Kobayashi K; Kanbe H; Harada H; Momose Y; Terakado S; Adachi Y; Midgley I
Yakugaku Zasshi; 2006 Mar; 126 Spec no.():237-45. PubMed ID: 16518089
[TBL] [Abstract][Full Text] [Related]
50. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.
McKillop D; Hutchison M; Partridge EA; Bushby N; Cooper CM; Clarkson-Jones JA; Herron W; Swaisland HC
Xenobiotica; 2004 Oct; 34(10):917-34. PubMed ID: 15764411
[TBL] [Abstract][Full Text] [Related]
51. Metabolism and Disposition of Siponimod, a Novel Selective S1P
Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
[TBL] [Abstract][Full Text] [Related]
52. Study on In Vitro Metabolism and In Vivo Pharmacokinetics of Beauvericin.
Yuan Y; Meng G; Li Y; Wu C
Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878215
[TBL] [Abstract][Full Text] [Related]
53. In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans.
Clémence C; Fouqueray P; Sébastien B
Drug Metab Dispos; 2020 Dec; 48(12):1330-1346. PubMed ID: 33020063
[TBL] [Abstract][Full Text] [Related]
54. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.
Hu ZY; Li XX; Du FF; Yang JL; Niu W; Xu F; Wang FQ; Li C; Sun Y
Acta Pharmacol Sin; 2013 Nov; 34(11):1437-48. PubMed ID: 24056706
[TBL] [Abstract][Full Text] [Related]
57. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
[TBL] [Abstract][Full Text] [Related]
59. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Sigafoos JF; Bowers GD; Castellino S; Culp AG; Wagner DS; Reese MJ; Humphreys JE; Hussey EK; O'Connor Semmes RL; Kapur A; Tao W; Dobbins RL; Polli JW
Drug Metab Dispos; 2012 Nov; 40(11):2090-101. PubMed ID: 22851617
[TBL] [Abstract][Full Text] [Related]
60. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent
Ma S; Cho S; Sahasranaman S; Zhao W; Pang J; Ding X; Dean B; Wang B; Hsu JY; Ware J; Salphati L
Drug Metab Dispos; 2023 Apr; 51(4):436-450. PubMed ID: 36623882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
